"Positive Results for Argenx's VYVGART Hytrulo in Nerve Disorder Study"

Zai Lab and argenx have announced positive topline results from the ADHERE study, which evaluated VYVGART Hytrulo in patients with chronic inflammatory demyelinating polyneuropathy (CIDP). The study met its primary endpoint, demonstrating a significantly lower risk of relapse with VYVGART Hytrulo compared to placebo. The therapy showed a 61% reduction in the risk of relapse and a favorable safety profile. Detailed data from the study will be presented at an upcoming medical meeting. CIDP is a rare autoimmune disease that affects the peripheral nervous system, causing weakness and sensory dysfunction in the limbs.